pDCs exhibit a dual role in TME: they can promote antitumor immunity by inducing cDC1 maturation and enhancing the effector functions of CD8+ T cells and NK cells, while simultaneously supporting tumor progression through immunosuppressive molecules (e.g., PD-L1, ICOSL, and IDO) [20]. This evidence concerns the gene CD8A and neoplasm.